![Stefan Mazgareanu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stefan Mazgareanu
Plus aucun poste en cours
Profil
Stefan Mazgareanu worked as a VP-Project Management & Preclinical Research at IDEA AG and as a Chief Operating Officer & Senior Vice President at Cardiorentis AG.
Anciens postes connus de Stefan Mazgareanu
Sociétés | Poste | Fin |
---|---|---|
Cardiorentis AG
![]() Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Directeur des opérations | 01/06/2016 |
IDEA AG
![]() IDEA AG Pharmaceuticals: MajorHealth Technology IDEA AG develops pain therapeutics and biopharmaceutical drugs. The firm develops and commercializes non-invasive therapeutic drugs and the targeted pain therapeutics for arthritic and osteoporosis-related inflammation, chronic pain and diseases. Its technology platform is based on proprietary carriers applied on skin and engineered to diminish side effects and increase drug potency. The company founded by Gregor Cevc in 1993 and is headquartered in Munich, Germany. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 2 |
---|---|
IDEA AG
![]() IDEA AG Pharmaceuticals: MajorHealth Technology IDEA AG develops pain therapeutics and biopharmaceutical drugs. The firm develops and commercializes non-invasive therapeutic drugs and the targeted pain therapeutics for arthritic and osteoporosis-related inflammation, chronic pain and diseases. Its technology platform is based on proprietary carriers applied on skin and engineered to diminish side effects and increase drug potency. The company founded by Gregor Cevc in 1993 and is headquartered in Munich, Germany. | Health Technology |
Cardiorentis AG
![]() Cardiorentis AG Pharmaceuticals: MajorHealth Technology Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland. | Health Technology |